MEANWELL CLIVE 4

What Happened

• Clive Meanwell, a director of Fractyl Health, received a derivative award: a stock option covering 22,500 shares reported on a Form 4 covering 2026-06-10. The grant is reported at $0.00 per share (total reported value $0.00) and is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-11.
• Transaction type: Award/Grant (code A) — derivative (stock option).
• Reported price: $0.00 per share; reported total value $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option was awarded under the company’s non-employee director compensation policy and will vest and become exercisable in a single installment on the earlier of (i) the next annual meeting of stockholders or (ii) the first anniversary of the grant, subject to continued board service.
• Timeliness: Filing covers the 6/10/2026 grant and was filed the next day (no late filing indicated).

Context

• This is a compensation stock option award for a non-employee director. Such awards are routine director pay and do not by themselves indicate immediate buying or selling intent. The option vests in one installment (per the footnote); whether Meanwell later exercises or sells shares will be reported in subsequent filings if and when those transactions occur.